Boston Scientific to acquire Claret Medical for up to $270 million

Boston Scientific signed an agreement to acquire Claret Medical, developer of the Sentinel Cerebral Embolic Protection System for TAVR procedures. The transaction includes $220 million in up-front cash and up to $50 million in milestone payments.

“This acquisition will expand our commercial portfolio to include an important adjunctive offering aimed at improving TAVR patient outcomes.”prnewswire.com

• 1 source
• prnewswire.comBoston Scientific Announces Agreement to Acquire Claret Medical, Inc.Boston Scientific CorporationJul 20, 2018

Summarized from public sources; check the original articles before acting on it.